Stock-based Compensation -Schedule of Stock Option Activity (Details) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($) $ / shares shares	Jun. 30, 2022 $ / shares
Options
Outstanding as of December 31, 2022 (in shares) | shares	3,356,937
Sesen Bio options assumed in the Merger (in shares) | shares	765,223
Exercised (in shares) | shares	(14,910)
Granted (in shares) | shares	2,747,152
Forfeited (in shares) | shares	(87,275)
Expired (in shares) | shares	(111,378)
Outstanding as of June 30, 2023 (in shares) | shares	6,655,749
Exercisable as of June 30, 2023 (in shares) | shares	2,961,132
Vested and expected to vest at June 30, 2023 (in shares) | shares	6,655,749
Weighted average exercise price
Outstanding as of December 31, 2022 (in USD per share)	$ 1.01
Sesen Bio options assumed in the Merger (in USD per share)	27.94
Exercised (in USD per share)	3.07
Granted (in USD per share)	7.17
Forfeited (in USD per share)	1.46
Expired (in USD per share)	23.52
Outstanding as of June 30, 2023 (in USD per share)	6.26
Exercisable as of June 30, 2023 (in USD per share)	6.98
Vested and expected to vest at June 30, 2023 (in USD per share)	6.26
Share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value (in USD per share)	$ 4.43	$ 0.75
Weighted average remaining contractual term (years)
Outstanding as of June 30, 2023	7 years 6 months
Exercisable as of June 30, 2023	5 years 2 months 12 days
Vested and expected to vest at June 30, 2023	7 years 6 months
Aggregate Intrinsic Value
Outstanding as of June 30, 2023 | $	$ 29,956
Exercisable as of June 30, 2023 | $	18,575
Vested and expected to vest at June 30, 2023 | $	$ 29,956